ClinicalTrials.gg
CompletedNCT00296465Updated May 19, 2011

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Three Dosage Strengths of Pulsatile GnRH

A Phase 2/3 interventional study of Pulsatile gonadotropin-releasing hormone (GnRH) and Clomiphene Citrate in InFertility, sponsored by Ferring Pharmaceuticals. Completed at 1 site in United States. Open to female participants aged 18 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2011-05-19.

Sponsored by Ferring Pharmaceuticals · Phase 2/3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
132
Allocation
Randomized
Ages
18 Years to 40 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 39 studies in Infertility by Ferring Pharmaceuticals — none open to participants now, 2 under way, none of them phase 3. Infertility · Ferring Pharmaceuticals.

Enrollment
18th of 27
132 · median 220
Started
2005
with 1 other
Phase 2/3
Only one
of the 39
Registered
2nd of 39
by date

Among the 39 studies in Infertility by Ferring Pharmaceuticals, this one is the 18th largest by enrollment of the 27 interventional ones that give a count, is one of 2 that started in 2005, is the only one in phase 2/3, and was the 2nd registered.

Infertility

2,089 studies on the registry are indexed under Infertility; 355 are open to participants now.

Browse Infertility studies →

Open to participants now

None of the 39 studies in Infertility by Ferring Pharmaceuticals is open now. The open studies under Infertility, anywhere →

Who these studies take

Of the 233 Infertility studies recruiting now, 43 (18%) set no upper age limit and 184 (79%) stop at 75 or younger; 27 take children under 18; 74 take healthy volunteers.

This study: 18 Years to 40 Years · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 39 studies in Infertility by Ferring Pharmaceuticals as a file.
02

Study summary

This study will be performed in approximately 132 women with anovulatory/oligoovulatory infertility.

Read the detailed description

This multicenter, randomized, double-blind, placebo-controlled study will be performed in approximately 132 women with anovulatory/oligoovulatory infertility. The treatment duration will be approximately 4 weeks with pulsatile GnRH or placebo and 5 days with Clomiphene Citrate or placebo. All subjects will be screened based on inclusion/exclusion criteria, medical/infertility history and general safety assessments. Subjects that complete screening will be dispensed 100 mg of oral progesterone twice a day for 10 days to induce uterine bleeding. On Cycle Day 5 from the start of bleeding the subject will be randomly assigned to 1 of 7 treatment groups. All subjects will be monitored weekly throughout the 4 week treatment period for ovulation and intercourse will be timed. All subjects will be required to return to the study center for a total of 8 visits. In addition, all subjects with a confirmed clinical pregnancy will be monitored until fetal heartbeat is confirmed at approximately 5-6 weeks gestation

03

Conditions studied

  • InFertility

Browse trials for

04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Females between the ages of 18 (or 19 in the State of Alabama) and 40 years.
  2. Infertile due to ovulatory dysfunction as described below:
  3. Positive progesterone withdrawal test following the screening visit.
  4. TSH (thyroid-stimulating hormone) levels within normal limits for the clinical laboratory or considered not (eg, secondary to exogenous thyroid medication) by the investigator
  5. Normal insulin sensitivity assessed as ratio of fasting blood glucose to fasting insulin > 4.5 at Screening
  6. Male partner with recent (within 6 months prior to screening) semen analysis showing normalcy according to the local laboratory normal criteria. If screening semen analysis is borderline, the couple will be accepted into the study only if a second sample obtained prior to screening is adequate.
  7. Presence of both ovaries, without evidence of clinically significant abnormality, as detected by transvaginal ultrasound
  8. Normal transvaginal ultrasound with respect to uterus and adnexa (eg, no hydrosalpinx)
  9. Hysterosalpingography or hysteroscopy or sonohysterogram documenting a uterine cavity consistent with expected normal function and patency of the fallopian tubes within the previous 3 years prior to screening (within 1 year prior to screening there should be no pelvic infection, endometriosis or pelvic surgery).
  10. Negative serum pregnancy test (qualitative) prior to the progesterone test
  11. Desire to become pregnant

Exclusion criteria

Exclusion Criteria

  1. Requires donor oocytes or sperm
  2. Previous and current use of infertility modifiers, including insulin-sensitizing drugs
  3. Primary amenorrhea/hypogonadotropic hypogonadism (eg, isolated gonadotropin deficiency or evidence of primary/premature ovarian failure)
  4. Presence of any systemic disease (eg, diabetes mellitus, pituitary tumor, anorexia nervosa).
  5. Surgical or medical condition which in the judgment of the Investigator or Sponsor may interfere with absorption, distribution, metabolism, or excretion of the drugs to be used.
  6. Any pregnancy within last 3 months prior to Screening.
  7. Patients with a (BMI) >30 at time of Screening
  8. Total testosterone and DHEA-S >1.5 times the laboratory range and prolactin > 20 ng/mL
  9. Presence of abnormal uterine bleeding of undetermined origin.
  10. Active or prior history of substance abuse
  11. History of chemotherapy (except for gestational conditions) or radiotherapy
  12. Currently breast feeding, pregnant or to pregnancy
  13. Refusal or inability to comply with the requirements of the Protocol for any reason, including scheduled clinic visits and laboratory tests.
  14. Documented intolerance or allergy to any of the medications used including the study medication
  15. Participation in any experimental drug study within 60 days prior to Screening
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
132 participants (actual)

Study arms

  • Experimental
    Lutrepulse® 5mcg IV

    5.0 mcg Pulsatile GnRH (Lutrepulse®) administered intravenously via portable infusion pump in a pulsatile fashion (every 90 minutes) for 4 weeks and oral placebo clomiphene citrate for 5 days

    Drug: Pulsatile gonadotropin-releasing hormone (GnRH) · Drug: Placebo Clomiphene Citrate

  • Experimental
    Lutrepulse® 10 mcg IV

    10.0 mcg Pulsatile GnRH (Lutrepulse®) administered intravenously via portable infusion pump in a pulsatile fashion (every 90 minutes) for 4 weeks and oral placebo clomiphene citrate for 5 days

    Drug: Pulsatile gonadotropin-releasing hormone (GnRH) · Drug: Placebo Clomiphene Citrate

  • Experimental
    Lutrepulse® 20 mcg SC

    20.0 mcg Pulsatile GnRH (Lutrepulse®) administered subcutaneously via portable infusion pump in a pulsatile fashion (every 90 minutes) for 4 weeks and oral placebo clomiphene citrate for 5 days

    Drug: Pulsatile gonadotropin-releasing hormone (GnRH) · Drug: Placebo Clomiphene Citrate

  • Placebo comparator
    Placebo IV

    Placebo Pulsatile GnRH (Lutrepulse®) administered intravenously via portable infusion pump in a pulsatile fashion (every 90 minutes) for 4 weeks and oral placebo clomiphene citrate for 5 days

    Drug: Placebo Pulsatile GnRH · Drug: Placebo Clomiphene Citrate

  • Placebo comparator
    Placebo SC

    Placebo Pulsatile GnRH (Lutrepulse®) administered subcutaneously via portable infusion pump in a pulsatile fashion (every 90 minutes) for 4 weeks and oral placebo clomiphene citrate for 5 days

    Drug: Placebo Pulsatile GnRH · Drug: Placebo Clomiphene Citrate

  • Active comparator
    Clomiphene Citrate/Placebo IV

    Oral clomiphene citrate (over encapsulated) for 5 days and Placebo Pulsatile GnRH (Lutrepulse®) administered intravenously via portable infusion pump in a pulsatile fashion (every 90 minutes) for 4 weeks

    Drug: Clomiphene Citrate · Drug: Placebo Pulsatile GnRH

  • Active comparator
    Clomiphene Citrate / Placebo SC

    Oral clomiphene citrate (over encapsulated) for 5 days and Placebo Pulsatile GnRH (Lutrepulse®) administered subcutaneously via portable infusion pump in a pulsatile fashion (every 90 minutes) for 4 weeks

    Drug: Clomiphene Citrate · Drug: Placebo Pulsatile GnRH

Interventions

  • Dosages as specified, administered either subcutaneously (SC) or intraveneously (IV) as specified, via portable infusion pump in a pulsatile fashion (every 90 minutes) for 4 weeks

    Also known as: Lutrepulse®

  • Oral clomiphene citrate (over encapsulated) for 5 days

    Also known as: Clomid

  • DrugPlacebo Pulsatile GnRH

    Administered either intravenously or subcutaneously via portable infusion pump in a pulsatile fashion (every 90 minutes) for 4 weeks

  • DrugPlacebo Clomiphene Citrate

    oral placebo clomiphene citrate for 5 days

06

What researchers measure

Primary outcomes

  1. Pregnancy rate

    Time frame: Day 16

Secondary outcomes

  1. Adverse events, including ovarian hyperstimulation syndrome (OHSS)

    Time frame: Day 1 to week 5

07

Study locations

1 site
  • Southern Fertility Center and Clinical Research
    Metairie, Louisiana 70002, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2005, a primary completion of Nov 2005 and a completion of Nov 2005. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 23, 2006
First posted
Feb 27, 2006
Start
Feb 2005
Primary completionActual
Nov 2005
CompletionActual
Nov 2005
Last update
May 19, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 19, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00296465
First posted
Feb 27, 2006
Start date
Feb 2005
Primary completion
Nov 2005
Completion
Nov 2005
Last update
May 19, 2011

Study contacts

Clinical Development Support
study director · Ferring Pharmaceuticals

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Gonadotropin-Releasing Hormone

Start the discussion